Previous close | 52.10 |
Open | 51.30 |
Bid | 77.30 |
Ask | 85.60 |
Strike | 930.00 |
Expiry date | 2024-08-16 |
Day's range | 51.30 - 52.10 |
Contract range | N/A |
Volume | |
Open interest | 2 |
Approval in patients with pJIA weighing 63kg or greater adds to Kevzara’s position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalgia rheumatica TARRYTOWN, N.Y. and CAMBRIDGE, MA, June 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration has approved Kevzara® (sarilumab) for the treatment of patients weighing 63 kg or greater with activ
Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 4.9% over the past month. Since the market usually pay for a...
Several stocks are breaking out and trading near all-time highs.